Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDTX NASDAQ:HROW NASDAQ:INBX NASDAQ:WVE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDTXCidara Therapeutics$62.90-0.6%$41.88$10.14▼$66.94$1.28B1.18646,574 shs302,038 shsHROWHarrow$31.23-1.7%$31.66$20.85▼$59.23$1.17B0.41442,110 shs530,570 shsINBXInhibrx Biosciences$21.60-1.5%$17.61$10.80▼$25.29$317.31M0.22145,336 shs58,806 shsWVEWAVE Life Sciences$8.63+6.5%$7.22$5.04▼$16.74$1.29B-0.951.67 million shs1.84 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDTXCidara Therapeutics-0.65%+1.70%+31.40%+190.00%+383.85%HROWHarrow-1.67%-13.71%+2.16%+20.91%+21.14%INBXInhibrx Biosciences-1.46%-6.41%+37.23%+77.78%+48.86%WVEWAVE Life Sciences+6.54%+2.74%+27.85%+6.54%+30.56%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCDTXCidara Therapeutics3.1487 of 5 stars2.62.00.04.61.71.70.0HROWHarrow2.5184 of 5 stars3.51.00.00.03.02.50.6INBXInhibrx Biosciences1.3386 of 5 stars0.01.00.04.60.62.51.3WVEWAVE Life Sciences4.7497 of 5 stars4.52.00.04.82.84.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDTXCidara Therapeutics 3.11Buy$57.29-8.93% DownsideHROWHarrow 3.00Buy$63.83104.40% UpsideINBXInhibrx Biosciences 2.00HoldN/AN/AWVEWAVE Life Sciences 2.93Moderate Buy$20.36135.89% UpsideCurrent Analyst Ratings BreakdownLatest INBX, HROW, WVE, and CDTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/31/2025WVEWAVE Life SciencesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$24.00 ➝ $21.007/28/2025WVEWAVE Life SciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$24.007/16/2025WVEWAVE Life SciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$16.007/11/2025HROWHarrowCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$76.007/9/2025CDTXCidara TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$69.006/30/2025CDTXCidara TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$59.006/24/2025CDTXCidara TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform6/24/2025CDTXCidara TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$35.00 ➝ $75.006/24/2025CDTXCidara TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$50.00 ➝ $68.006/23/2025CDTXCidara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$41.00 ➝ $53.006/23/2025CDTXCidara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$36.00 ➝ $54.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDTXCidara Therapeutics$1.27M998.48N/AN/A$14.92 per share4.22HROWHarrow$199.61M5.74$0.13 per share232.26$1.95 per share16.02INBXInhibrx Biosciences$200K1,563.84$113.68 per share0.19$9.23 per share2.34WVEWAVE Life Sciences$108.30M12.68N/AN/A$0.88 per share9.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDTXCidara Therapeutics-$169.83M-$29.47N/AN/AN/AN/A-73.04%-54.28%8/7/2025 (Estimated)HROWHarrow-$17.48M-$0.56N/A78.08N/A-10.19%-25.01%-4.27%8/11/2025 (Estimated)INBXInhibrx Biosciences$1.69B$116.750.19N/AN/AN/A-85.12%-58.90%8/12/2025 (Estimated)WVEWAVE Life Sciences-$97.01M-$0.84N/AN/AN/AN/A-78.45%-41.51%N/ALatest INBX, HROW, WVE, and CDTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025INBXInhibrx Biosciences-$2.92N/AN/AN/AN/AN/A8/11/2025Q2 2025HROWHarrow$0.01N/AN/AN/A$64.23 millionN/A8/7/2025Q2 2025CDTXCidara Therapeutics-$1.87N/AN/AN/AN/AN/A7/30/2025Q2 2025WVEWAVE Life Sciences-$0.29-$0.31-$0.02-$0.31$11.52 million$8.70 million5/14/2025Q4 2024INBXInhibrx Biosciences-$2.55-$2.80-$0.25-$2.80N/AN/A5/8/2025Q1 2025CDTXCidara Therapeutics-$5.45-$1.66+$3.79-$1.66N/AN/A5/8/2025Q1 2025HROWHarrow$0.02-$0.38-$0.40-$0.50$57.00 million$47.83 million5/8/2025Q1 2025WVEWAVE Life Sciences-$0.27-$0.29-$0.02-$0.29$11.65 million$9.18 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCDTXCidara TherapeuticsN/AN/AN/AN/AN/AHROWHarrowN/AN/AN/AN/AN/AINBXInhibrx BiosciencesN/AN/AN/AN/AN/AWVEWAVE Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDTXCidara TherapeuticsN/A3.873.87HROWHarrow2.010.910.85INBXInhibrx Biosciences1.045.125.12WVEWAVE Life SciencesN/A2.562.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDTXCidara Therapeutics35.82%HROWHarrow72.76%INBXInhibrx Biosciences82.46%WVEWAVE Life Sciences89.73%Insider OwnershipCompanyInsider OwnershipCDTXCidara Therapeutics3.89%HROWHarrow15.16%INBXInhibrx Biosciences17.09%WVEWAVE Life Sciences23.98%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDTXCidara Therapeutics9020.16 million19.38 millionNo DataHROWHarrow18036.69 million31.12 millionOptionableINBXInhibrx Biosciences16614.48 million12.00 millionOptionableWVEWAVE Life Sciences240159.14 million118.26 millionOptionableINBX, HROW, WVE, and CDTX HeadlinesRecent News About These CompaniesWells Fargo & Company Cuts WAVE Life Sciences (NASDAQ:WVE) Price Target to $21.00August 2 at 2:07 AM | americanbankingnews.comWAVE Life Sciences (NASDAQ:WVE) Price Target Lowered to $21.00 at Wells Fargo & CompanyAugust 1 at 1:05 PM | marketbeat.comWAVE Life Sciences Ltd (WVE) Q2 2025 Earnings Call Highlights: Progress in RNA Editing Amid ...July 31 at 6:15 AM | finance.yahoo.comWave (WVE) Q2 Revenue Drops 56%July 31 at 3:10 AM | fool.comWAVE Life Sciences Ltd. (NASDAQ:WVE) Receives Consensus Rating of "Moderate Buy" from AnalystsJuly 31 at 2:44 AM | marketbeat.comWave Life Sciences signals key Q3 and Q4 data catalysts as INHBE and AATD programs advanceJuly 31 at 2:14 AM | msn.comWave Life Sciences Ltd. (WVE) Q2 2025 Earnings Call TranscriptJuly 30 at 10:05 PM | seekingalpha.comWAVE Life Sciences Ltd (WVE) Q2 2025 Earnings Report Preview: What To ExpectJuly 30 at 3:11 PM | finance.yahoo.comWaveLife Flat on Q2 ResultsJuly 30 at 10:11 AM | baystreet.caWave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue EstimatesJuly 30 at 10:01 AM | zacks.comWave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business UpdateJuly 30 at 7:30 AM | globenewswire.comWave Life Sciences Q2 2025 Earnings PreviewJuly 29, 2025 | msn.comOppenheimer Initiates Coverage of Wave Life Sciences (WVE) with Outperform RecommendationJuly 29, 2025 | msn.comWAVE Life Sciences (NASDAQ:WVE) Shares Gap Up - Time to Buy?July 28, 2025 | marketbeat.comWAVE Life Sciences (WVE) to Release Quarterly Earnings on WednesdayJuly 25, 2025 | marketbeat.comNew York State Common Retirement Fund Acquires 41,429 Shares of WAVE Life Sciences Ltd. (NASDAQ:WVE)July 25, 2025 | marketbeat.comWave Life Sciences Second Quarter 2025 Financial Results Scheduled for July 30, 2025July 23, 2025 | globenewswire.comHussman Strategic Advisors Inc. Has $848,000 Stake in WAVE Life Sciences Ltd. (NASDAQ:WVE)July 19, 2025 | marketbeat.comPrincipal Financial Group Inc. Acquires 59,399 Shares of WAVE Life Sciences Ltd. (NASDAQ:WVE)July 19, 2025 | marketbeat.comBreaking Down WAVE Life Sciences: 4 Analysts Share Their ViewsJuly 16, 2025 | benzinga.comCitigroup Initiates Coverage of Wave Life Sciences (WVE) with Buy RecommendationJuly 16, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeINBX, HROW, WVE, and CDTX Company DescriptionsCidara Therapeutics NASDAQ:CDTX$62.90 -0.41 (-0.65%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$60.00 -2.90 (-4.61%) As of 08/1/2025 06:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.Harrow NASDAQ:HROW$31.23 -0.53 (-1.67%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$31.85 +0.62 (+1.99%) As of 08/1/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.Inhibrx Biosciences NASDAQ:INBX$21.60 -0.32 (-1.46%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$21.64 +0.04 (+0.19%) As of 08/1/2025 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.WAVE Life Sciences NASDAQ:WVE$8.63 +0.53 (+6.54%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$8.39 -0.24 (-2.79%) As of 08/1/2025 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
